A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin.

Trial Profile

A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2016

At a glance

  • Drugs Imatinib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms BUS255
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 19 Jan 2016 Planned End Date changed from 1 Oct 2014 to 1 Aug 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top